GWPH Stock, GW Pharmaceuticals Plc Information

GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group s lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex R Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW has assembled a large in house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant based prescription pharmaceutical products. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.